Repligen (NASDAQ:RGEN) Research Coverage Started at Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of Repligen (NASDAQ:RGEN) in a report released on Tuesday morning, MarketBeat.com reports. The firm issued a hold rating and a $165.00 price objective on the biotechnology company’s stock.

Several other research firms have also commented on RGEN. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Trading Down 0.5 %

Shares of Repligen stock opened at $146.54 on Tuesday. The stock has a market cap of $8.21 billion, a PE ratio of -396.04, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. The firm has a fifty day moving average price of $144.07 and a 200 day moving average price of $141.81. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the business posted $0.23 EPS. The company’s revenue was up 9.7% on a year-over-year basis. Equities research analysts predict that Repligen will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its position in shares of Repligen by 937.8% during the second quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company’s stock worth $3,806,000 after purchasing an additional 27,280 shares in the last quarter. Raymond James & Associates grew its holdings in shares of Repligen by 3.7% during the second quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock worth $6,948,000 after buying an additional 1,951 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Repligen by 6.4% during the second quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company’s stock worth $390,000 after buying an additional 187 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Repligen in the second quarter valued at about $273,000. Finally, Slow Capital Inc. lifted its stake in shares of Repligen by 10.7% in the second quarter. Slow Capital Inc. now owns 16,165 shares of the biotechnology company’s stock worth $2,038,000 after buying an additional 1,558 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.